Literature DB >> 24800798

[Acute coronary syndrome after chemotherapy].

Mijntje B Vastbinder1, Henk Drost, Erik W Muller.   

Abstract

Systemic therapy for malignancy may be accompanied by an acute coronary syndrome (ACS), regardless of cardiovascular risk factors. We present three patients with few cardiovascular risk factors and no history of cardiovascular disease, who suffered an ACS within a week of starting systemic treatment of colorectal cancer, non-Hodgkin's lymphoma and breast cancer, respectively. In all three patients, systemic anti-cancer therapy was continued after making individualised adjustments to the treatment regimen. It is important to recognize the possible relationship between chemotherapy - including the oral compound capecitabine - and ACS, and to withhold systemic anti-cancer treatment until the ACS is adequately treated. Subsequently, a decision has to be made regarding the continuation of the systemic anti-cancer treatment. Factors to be included in decision making are the intent of the treatment (curative or palliative), the availability of a regimen with less cardiovascular toxicity but comparable efficacy, the outcome of the ACS and the patient's wishes.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24800798

Source DB:  PubMed          Journal:  Ned Tijdschr Geneeskd        ISSN: 0028-2162


  1 in total

1.  Outcome of patients admitted with acute coronary syndrome on palliative treatment: insights from the nationwide AMIS Plus Registry 1997-2014.

Authors:  Paul Erne; Dragana Radovanovic; Burkhardt Seifert; Osmund Bertel; Philip Urban
Journal:  BMJ Open       Date:  2015-03-02       Impact factor: 2.692

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.